Download PDF
Planta Med 2002; 68(4): 297-301
DOI: 10.1055/s-2002-26743
Original Paper
Pharmacology
© Georg Thieme Verlag Stuttgart · New York

Protodioscin (NSC-698 796): Its Spectrum of Cytotoxicity Against Sixty Human Cancer Cell Lines in an Anticancer Drug Screen Panel

Ke Hu1 , Xinsheng Yao2
  • 1Department of Pharmaceutical Sciences, School of Pharmacy, State University of New York at Buffalo, Buffalo, New York, USA
  • 2Department of Natural Products Chemistry, Shenyang Pharmaceutical University, Shenyang, Liaoning, China
Further Information

Publication History

June 19, 2001

August 24, 2001

Publication Date:
02 May 2002 (online)

    Permissions and Reprints

Abstract

Protodioscin (NSC-698 796) is a furostanol saponin isolated from the rhizome of Dioscorea collettii var. hypoglauca (Dioscoreaceae), a Chinese herbal remedy for the treatment of cervical carcinoma, carcinoma of urinary bladder and renal tumor for centuries. To systematically evaluate its potential anticancer activity, protodioscin was tested for cytotoxicity in vitro against 60 human cancer cell lines in the NCI’s (National Cancer Institute, USA) anticancer drug screen. As a result, protodioscin was cytotoxic against most cell lines from leukemia and solid tumors in the NCI’s human cancer panel, especially selectively against one leukemia line (MOLT-4), one NSCLC line (A549/ATCC), two colon cancer lines (HCT-116 and SW-620), one CNS cancer line (SNB-75), one melanoma line (LOX IMVI), and one renal cancer line (786 - 0) with GI50 ≤ 2.0 μM. In the general view of mean graphs, leukemia, colon cancer and prostate cancer are the most sensitive subpanels, while ovarian cancer is the least sensitive subpanel. Based on an analysis of COMPARE computer program with protodioscin as a seed compound, no compounds in the NCI’s anticancer drug screen database have cytotoxicity patterns (mean graphs) similar to those of protodioscin, indicating that a potential novel mechanism of anticancer action is involved.

Key words

Cytotoxicity - protodioscin - NCI’s anticancer drug screen - NSC-698 796 - Dioscorea collettii var. hypoglauca - Dioscoreaceae

References

  • 1 Kobayashi H, Namikoshi M, Yoshimoto T, Yokochi T. A screening method for antimitotic and antifungal substances using conidia of Pyricularia oryzae, modification and application to tropical marine fungi.  Journal of Antibiotics. 1996;  49 873-9
    PubMedGoogle Scholar
  • 2 Hu K, Dong A J, Yao X S, Kobayashi H, Iwasaki S. Antineoplastic agents; I. Three spirostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca .  Planta Medica. 1996;  62 573-5
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Hu K, Dong A J, Yao X S, Kobayashi H, Iwasaki S. Antineoplastic agents; II. Four furostanol glycosides from rhizomes of Dioscorea collettii var. hypoglauca .  Planta Medica. 1997;  63 161-5
    PubMedGoogle Scholar
  • 4 Hu K, Dong A J, Yao X S, Kobayashi H, Iwasaki S. A furostanol glycoside from rhizomes of Dioscorea collettii var. hypoglauca .  Phytochemistry. 1997;  44 1339-42
    CrossrefPubMedGoogle Scholar
  • 5 Hu K, Kobayashi H, Dong A J, Iwasaki S, Yao X S. A new pregnane glycoside from Dioscorea collettii var. hypoglauca .  Chinese Chemical Letters. 1998;  9 739-42
    PubMedGoogle Scholar
  • 6 Hu K, Dong A J, Kobayshi H, Iwasaki S, Jing Y K, Yao X S. A new pregnane glycoside from Dioscorea collettii var. hypoglauca .  Journal of Natural Products. 1999;  62 299-301
    CrossrefPubMedGoogle Scholar
  • 7 Boyd M R. Status of the NCI preclinical antitumor drug discovery screen. In: Cancer: Principles and practice of oncology updates. De Vita VT Jr, Hellman S, Rosenberg SA, editors Philadelphia: Lippincott; 1989: 1-12
    Google Scholar
  • 8 Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo , Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.  Journal of National Cancer Institute. 1991;  83 757-66
    CrossrefPubMedGoogle Scholar
  • 9 Grever M R, Schepartz S A, Chabner B A. The National Cancer Institute cancer drug discovery and development program.  Seminars in Oncology. 1992;  19 622-36
    PubMedGoogle Scholar
  • 10 Alley M C, Scudiero D A, Monks A P, Hursey M L, Czerwinski M J, Fine D L, Abbott B J, Mayo J G, Shoemaker R H, Boyd M R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.  Cancer Research. 1988;  48 589-601
    PubMedGoogle Scholar
  • 11 Skehan P, Storeng R, Scudiero D A, Monks A P, McMahon J, Vistica D T, Warren J T, Bokesch H, Kenney S, Boyd M R. New colorimetric cytotoxicity assay for anticancer drug screening.  Journal of National Cancer Institute. 1990;  82 1107-12
    CrossrefPubMedGoogle Scholar
  • 12 Rubinstein L V, Shoemaker R H, Paull K D, Simon R M, Tosini S, Skehan P, Scudiero D A, Monks A P, Boyd M R. Comparison of in vitro anticancer drug screening data generated with a tertrazolium assay versus a protein assay against a diverse panel of human tumor cell lines.  Journal of National Cancer Institute. 1990;  82 1113-8
    CrossrefPubMedGoogle Scholar
  • 13 Paull K D, Shoemaker R H, Hodes L, Monks A P, Scudiero D A, Rubinstein L V, Plowman J, Boyd M R. Display and analysis of pattern of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm.  Journal of National Cancer Institute. 1989;  81 1088-92
    CrossrefPubMedGoogle Scholar
  • 14 Weinstein J N, Kohn K W, Grever M R, Viswanadhan V N, Rubinstein L V, Monks A P, Scudiero D A, Welch L, Koutsoukos A D, Chiausa A J, Paull K D. Neural computing in cancer drug development: Predicting mechanism of action.  Science. 1992;  258 447-51
    PubMedGoogle Scholar
  • 15 Boyd M R, Paull K D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen.  Drug Development Research. 1995;  34 91-109
    CrossrefPubMedGoogle Scholar
  • 16 Bates S E, Fojo A T, Weinstein J N, Myers T G, Alvarez M, Paull K D, Chabner B A. Molecular targets in the National Cancer Institute drug screen.  Journal of Cancer Research and Clinical Oncology. 1995;  121 495-500
    CrossrefPubMedGoogle Scholar
  • 17 Monks A P, Scudiero D A, Johnson G S, Paull K D, Sausville E A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets.  Anti-Cancer Drug Design. 1997;  12 533-41
    PubMedGoogle Scholar
  • 18 Weinstein J N, Myers T G, O’Connor P M, Friend S H, Fornace A J, Kohn K W, Fojo T, Bates S E, Rubinstein L V, Anderson N L, Buolamwini J K, van Osdol W W, Monks A P, Scudiero D A, Sausville E A, Zaharevitz D W, Bunow B, Viswanadhan V N, Johnson G S, Wittes R E, Paull K D. An information-intensive approach to the molecular pharmacology of cancer.  Science. 1997;  275 343-9
    CrossrefPubMedGoogle Scholar

Dr. Ke Hu

Department of Pharmaceutical Sciences

School of Pharmacy

State University of New York at Buffalo

539 Hochstetter Hall

Buffalo, NY 14260

USA

Phone: +1 (716)-645-2842 ext. 229

Fax: +1 (716)-645-3693

Email: kehu@ascu.buffalo.edu

      >